In Europe and in the United States, the 5-year survival rate for individuals affected by Hodgkin's disease (HD) before 20 years of age is now over 90% and the corresponding rate for nonHodgkin's lymphoma (NHL) is in the 70% range. 1 Recent studies indicate that lymphoma survivors with a family history of cancer experience high risks of second primary neoplasms, which are the leading causes of death after recurrence. 2 However, the effect of a parental history of cancer on the development of second neoplasms at the same site than the parents (concordant cancer sites) has not yet been investigated. The continuous improvement in lymphoma survival makes this question particularly relevant.
We have used the Swedish Family-Cancer Database to investigate whether the risk of second concordant cancers after lymphoma is particularly increased among the offspring of cancer patients. The Database includes persons born in Sweden after 1931 with their biological parents, totaling more than 11.5 million persons and more than 1.2 million tumor notifications. (For a detailed description of the Database and   its last update see references. 3,4 ) In our analyses, 3084 HD and 7699 NHL patients were followed up from the diagnosis of lymphoma until death, detection of a second primary cancer, emigration or 31 December, 2004, whichever came first. Lymphoma survivors with a parental history of cancer were identified and followed up separately. The cumulative incidences of second concordant malignancies among lymphoma patients were estimated by the Kaplan-Meier method and they were compared with the rates in the general Swedish population by standardized incidence ratios (SIRs) and 95% confidence intervals (CIs), adjusting for the covariates age (5-year bands), sex, socioeconomic index (six groups), region (four groups) and calendar year (before 1965, 1965-1969, y, 2000-2004) . Table 1 shows the estimated relative risks for those cancer sites at which at least two lymphoma survivors were affected by second neoplasms at the same site than their parents. The median elapsed time from diagnosis of lymphoma to the detection of the 84 breast tumors was 13 years (range 1-39 years). The cumulative incidence of breast cancer 30 years after diagnosis of lymphoma was 3.4%. The risk of breast cancer was 2.39 times higher among female lymphoma Table 1 Relative risk (SIR) of second cancer and second cancer at the same site than the parents following lymphoma Abbreviations: CI, confidence interval; CI-30, cumulative incidence 30 years after lymphoma diagnosis (%); N, number of lymphoma survivors with second neoplasms; NF, number of followed individuals; P, P-value for an increased risk compared to all lymphoma survivors; SIR, standardized incidence ratio; YSC, years to second cancer (median, range). Bold signifies increased risk compared to the general Swedish population.
Letters to the Editor patients than in the general Swedish population. In particular, the SIR of breast cancer after lymphoma was 5.57 in women with a maternal history of breast cancer (among the 552 lymphoma patients with a maternal history of breast cancer, seven developed breast cancer, the P-value for an increased SIR in women with a maternal history was P ¼ 0.016). Similarly, the SIR of lung cancer after lymphoma (3.37) resulted significantly increased among patients with a parental history of lung cancer (SIR ¼ 8.38, P ¼ 0.011). Lymphoma patients with a concordant family history also showed the increased SIRs for squamous cell skin cancer (SIR ¼ 35.1 versus 6.83, Po0.001) and urinary bladder cancer (SIR ¼ 16.9 versus 2.06, Po0.001).
Among NHL patients, those with a site-specific parental history were at significantly higher risks of developing second neoplasms in the breast (SIR ¼ 8.44 versus 2.62, P ¼ 0.008) the urinary bladder (SIR ¼ 18.7 versus 2.85, P ¼ 0.001) and the stomach (SIR ¼ 9.79 versus 2.21, P ¼ 0.025). The SIR of breast cancer after HD (3.54) was higher when the women had a maternal history of breast cancer (9.69), but the difference between SIRs was not statistically significant. By contrast, the SIR of lung cancer after HD (6.16) was significantly higher among individuals with a parental history of lung cancer (SIR ¼ 32.6, Po0.001). Also the relative risk of squamous cell skin cancer (SIR ¼ 7.51) increased in HD patients with a family history of skin cancer (SIR ¼ 44.7, P ¼ 0.009).
The present results are in agreement with a recent international study which has found that survivors of childhood HD have a 9-16-fold increased risk of developing second primary tumors compared with the general population; the corresponding figures were 2-6 for NHL. 5 The novel aspect of the present study was the investigation of the effect of a site-specific parental history of cancer on the risk for second primary concordant neoplasms. In the Swedish Family-Cancer Database, parents are registered at the time of birth of the child, thus allowing tracking of 'biological' parents in spite of divorce and remarriage. The nationwide complete coverage of the Database and the reliability of cancer data, compulsorily reported by clinicians who diagnosed the neoplasms and by pathologists/cytologists, represent important advantages of the present study in comparison to interviews or questionnaires. Although the sample size permitted to detect some interactions between lymphoma diagnosis and parental history of concordant cancer, the study was limited by the fact that the maximum age in our cohort was 72 years, below the age at which the risk of solid neoplasms is the highest. Another important limitation was the unavailability of information on treatment.
Previous studies have found HD survivors to be at an increased risk of lung cancer. 5, 6 Moreover, smokers may experience a higher risk of lung cancer attributable to radiotherapy than nonsmokers. 7 We found that, 30 years after diagnosis of HD, the cumulative risk of lung cancer in patients with a parental history was 15.8% and the SIR was 32.6. These results may point out to the necessity of motivating lymphoma survivors to adopt healthy lifestyles. The association of second skin squamous cell cancer with both types of lymphoma, HD and NHL, adds consistency to our data. Previous analyses of the database have shown that the risk of breast cancer in women with a maternal history of breast cancer is about 1.9 times higher than the average population risk. 8 If maternal history and treatment of NHL had a multiplicative effect, the expected SIR in NHL patients with a maternal history of breast cancer would be 1.9 Â 2.6 ¼ 4.9. The observed SIR of 8.44 may indicate greater than multiplicative interaction effects. Analogous conclusions can be drawn for urinary bladder (parental SIR 1.7) and stomach (parental SIR 1.5) cancers. A family history of cancer in lymphoma survivors is relatively rare (for example 552/ 10783 ¼ 5.1% for maternal breast cancer in our cohort) but the high risks of second tumors for those with a family history are of practical importance, calling for increased surveillance of cancer at the involved sites.
